





Fax Completed Form To 1.833.404.2392

Prescriber Help Desk 1.833.587.2012

Online covermymeds.com/main/prior-authorization-forms/

Request for Prior Authorization BIOLOGICALS FOR HIDRADENITIS SUPPURATIVA

(PLEASE PRINT - ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name	, , , , , , , , , , , , , , , , , , ,	DOB	
Patient address				
Provider NPI	Prescriber name		Phone	
Prescriber address			Fax	
Pharmacy name	Address		Phone	
Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.				
Pharmacy NPI	Pharmacy fax	NDC		
Prior authorization (PA) is required for biologicals FDA approved or compendia indicated for the treatment of Hidradenitis Suppurativa (HS). Payment for non-preferred biologic agents will be considered only for cases in which there is documentation of a previous trial and therapy failure with a preferred biologic agent. Payment will be considered under the following conditions: 1) Request adheres to all FDA approved labeling for requested drug and indication, including age, dosing, contraindications, warnings and precautions, drug interactions, and use in special populations. 2) Patient has a diagnosis of moderate to severe HS with Hurley Stage II or III disease; and 3) Patient has at least three (3) abscesses or inflammatory nodules; and 4) Patient has documentation of adequate trials and therapy failures with the following: a) Daily treatment with topical clindamycin; b) Oral clindamycin plus rifampin; c) Maintenance therapy with a preferred tetracycline. If criteria for coverage are met, initial requests will be given for 4 months. Additional authorizations will be considered upon documentation of clinical response to therapy. Clinical response is defined as at least a 50% reduction in total abscess and inflammatory nodule count with no increase in abscess count and no increase in draining fistula count from initiation of therapy. The required trials may be overridden when documented evidence is provided that use of these agents would be medically contraindicated.				
	-Preferred			
Adalimumab-aacf Bimzelx				
☐ Adalimumab-adbm ☐ Cosentyx				
Adalimumab-fkjp Other Humira Biosimilar:				
☐ Humira				
Simlandi				
☐ Yusimry				
Strength	Dosage Instructions	Quantity	Days Supply	
Diagnosis:				
☐ Hidradenitis Suppurativa: Hurley Stage ☐ I ☐ II ☐ III				
Other:				
Does patient have at least three	(3) absesses or inflammatory node	ules?		
☐ No ☐ Yes: Abscess/Nodule	e count:	Date obt	ained:	

Rev. 4/25 Page 1 of 2







Fax Completed Form To 1.833.404.2392 Prescriber Help Desk

1.833.587.2012

Online

covermymeds.com/main/

prior-authorization-forms/

Request for Prior Authorization BIOLOGICALS FOR HIDRADENITIS SUPPURATIVA

(PLEASE PRINT - ACCURACY IS IMPORTANT)

Topical Clindamycin Trial Name/Dose:				
Oral Clindamycin Plus Rifampin Trial:				
Clindamycin: Dose:	Trial dates:			
Reason for failure:				
Rifampin: Dose:	Trial dates:			
Reason for failure:				
Maintenance Preferred Tetracycline Trial:				
Name/Dose:	Trial dates:			
Reason for failure:				
Renewals				
Document response to therapy:				
Abscess/Nodule Count: Increase Decrease (provide count): Date obtained:				
Has patient had an increase in draining fistula count since initiation of therapy?				
Other medical conditions to consider:				
Possible drug interactions/conflicting drug therapies:				
ttach lab results and other documentation as necessary.				
Prescriber signature (Must match prescriber listed above.)	ate of submission			

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Health and Human Services, that the member continues to be eligible for Medicaid.

Rev. 4/25 Page 2 of 2